Study Evaluating Efficacy and Safety of OSU6162 in the Treatment of Residual Symptoms After Stroke
Status:
Completed
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
Following stroke, a recovery process is promptly initiated, which leads to a partial
rehabilitation. However, a number of disabling residual symptoms may persist for years and
include mental fatigue, depression, cognitive deficits, neurological problems and more. In
the lack of an effective treatment these symptoms will lead to major consequences for the
individual and the surrounding society. OSU6162 has in earlier clinical studies of stroke
patients shown evidence of a favorable effect on residual symptoms, especially mental
fatigue, together with a mild side effect profile.
In this phase II, randomized, placebo-controlled, two-armed study, a 16 week OSU6162
treatment will be compared to an equally long placebo treatment in patients with residual
symptoms following stroke.